TNF-α Inhibitor Treatment for Crohn’s Disease: Comparative Review of Post Therapy Malignancy between Infliximab and Adalimumab | Chapter 08 | Modern Advances in Pharmaceutical Research Vol. 2
The association between chronic
inflammatory disease and cancer has been well established through years of
research. In corollary, progressive resistance to chimeric monoclonal
antibodies has been reported in literature. The purpose of this investigation
was to establish the overall trend of the chimeric monoclonal antibody
(Infliximab) failure compared with human monoclonal antibody (Adalimumab). It
was opined that this failure may result in subclinical yet cancer-inducing
inflammation that could be measurable in patient populations undergoing the
therapy by examining cancer prevalence. An overall trend of increased incidence
of new malignancy in patient populations on Infliximab compared with Adalimumab
was confirmed from the literature reviewed. There was also a significant trend
of developing Gastrointestinal (GI) related cancer in patients on Infliximab,
which corresponds with the majority of the progression process in Crohn’s
disease. It was opined that future observations in clinical practice will lead
to the phasing out of Infliximab as a front-line monoclonal antibody in the
treatment of Crohn’s disease in favor of less immunogenic monoclonal
antibodies. In conclusion an increased incidence of both general and GI
malignancies has been widely reported in patient populations undergoing
Infliximab therapy than with Adalimumab.
Author(s) Details
Danil Hammoudi, MD
Department of Pathology,
Saint James School of Medicine, BWI, Anguilla.
Adekunle Sanyaolu, PhD
Department of Medical Microbiology
and Immunology, Saint James School of Medicine, BWI, Anguilla
Nirav Nagarsheth, MD, MBA
Department of Pathology,
Saint James School of Medicine, BWI, Anguilla.
Jason Kimbel, M.D., MHA
Department of Pathology,
Saint James School of Medicine, BWI, Anguilla.
Amos Abioye, PhD
Department of Pharmacy,
Leicester School of Pharmacy, De Montfort University, Leicester, LE1 9BH,
United Kingdom.
View Volume: https://doi.org/10.9734/bpi/mapr/v2
Comments
Post a Comment